As previous reviews have focused on either BCG or anti‐PD‐1/PD‐L1 immunotherapies, rarely both, here we review bladder cancer BCG and anti‐PD1/PD‐L1 immunotherapies together to explore our knowledge and the potential to improve immunotherapy. The gene discussed is PDCD1; the disease is urinary bladder cancer.